Brief: Hls Therapeutics Q1 Loss Per Share $0.14

HLS Therapeutics

09/05/2019 11:58

HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES Q1 2019 FINANCIAL RESULTS
    * Q1 REVENUE OF $13.2 MILLION, ADJUSTED EBITDA OF $8.3
MILLION AND
CASH FROM OPERATIONS OF $8.3 MILLION
    * Q1 LOSS PER SHARE $0.14
    * AS AT MARCH 31, 2019, COMPANY HAD CASH AND CASH
EQUIVALENTS OF
$12.8 MILLION, UP FROM $10.9 MILLION AT DECEMBER 31, 2018.

Source text for Eikon:  ID:nCNW1Tkrha 
Further company coverage:  HLS.TO